Official reprint from UpToDate®
www.uptodate.com ©2015 UpToDate®

Pathophysiology of seizures and epilepsy

Carl E Stafstrom, MD, PhD
Jong M Rho, MD
Section Editor
Timothy A Pedley, MD
Deputy Editor
April F Eichler, MD, MPH


An epileptic seizure is an episode of neurologic dysfunction in which abnormal neuronal firing is manifest clinically by changes in motor control, sensory perception, behavior, and/or autonomic function. Epilepsy is the condition of recurrent spontaneous seizures arising from aberrant electrical activity within the brain. While anyone can experience a seizure under the appropriate pathophysiological conditions, epilepsy suggests an enduring alteration of brain function that facilitates seizure recurrence. Epileptogenesis is the process by which the normal brain becomes prone to epilepsy [1].

The aberrant electrical activity that underlies epilepsy is the result of biochemical processes at the cellular level promoting neuronal hyperexcitability and neuronal hypersynchrony. However, a single neuron, discharging abnormally, is insufficient to produce a clinical seizure, which occurs only in the context of large neuronal networks. Several key cortical and subcortical structures are involved in generating a seizure.

This topic will review the cellular basis for focal and generalized seizure activity, with specific attention to ion channels, the essential currency of neuronal excitability, and the hippocampus, one of the most seizure-prone areas of the brain. The pharmacology of antiepileptic drugs and issues related to the assessment and management of patients with epilepsy are discussed separately. (See "Antiepileptic drugs: Mechanism of action, pharmacology, and adverse effects" and "Overview of the management of epilepsy in adults".)


Epilepsy is not a singular disease, but is heterogeneous in terms of clinical expression, underlying etiologies, and pathophysiology (table 1). As such, specific mechanisms and pathways underlying specific seizure types may vary. Epileptic seizures are broadly classified according to their site of origin and pattern of spread (figure 1).

Focal seizures arise from a localized region of the brain and have clinical manifestations that reflect that area of brain. Focal discharges can remain localized or they can spread to nearby cortical areas, to subcortical structures and/or transmit through commissural pathways to involve the whole cortex. The latter sequence describes the secondary generalization of focal seizures. As an example, a seizure arising from the left motor cortex may cause jerking movements of the right upper extremity. If epileptiform discharges spread to adjacent areas and then the entire brain, a secondary generalized tonic-clonic seizure ensues.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2015. | This topic last updated: Jul 30, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2015 UpToDate, Inc.
  1. Pitkänen A, Lukasiuk K. Molecular and cellular basis of epileptogenesis in symptomatic epilepsy. Epilepsy Behav 2009; 14 Suppl 1:16.
  2. McCormick DA, Contreras D. On the cellular and network bases of epileptic seizures. Annu Rev Physiol 2001; 63:815.
  3. Faingold CL. Emergent properties of CNS neuronal networks as targets for pharmacology: application to anticonvulsant drug action. Prog Neurobiol 2004; 72:55.
  4. Chang BS, Lowenstein DH. Epilepsy. N Engl J Med 2003; 349:1257.
  5. Stafstrom CE. Recognizing seizures and epilepsy: insights from pathophysiology. In: Epilepsy, Miller JW, Goodkin HP. (Eds), Wiley Blackwell, Hoboken 2014. p.3-9.
  6. Rho JM, Stafstrom CE. Neurophysiology of epilepsy. In: Pediatric Neurology: Principles and Practice, 4th, Swaiman KF, Ashwal S, Ferreiro DM. (Eds), Mosby Elsevier, Philadelphia 2006. p.991.
  7. Stafstrom CE. Persistent sodium current and its role in epilepsy. Epilepsy Curr 2007; 7:15.
  8. Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 2005; 57:397.
  9. Lossin C. A catalog of SCN1A variants. Brain Dev 2009; 31:114.
  10. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004; 5:553.
  11. Catterall WA, Striessnig J, Snutch TP, et al. International Union of Pharmacology. XL. Compendium of voltage-gated ion channels: calcium channels. Pharmacol Rev 2003; 55:579.
  12. Cooper EC, Jan LY. M-channels: neurological diseases, neuromodulation, and drug development. Arch Neurol 2003; 60:496.
  13. Stephen LJ, Brodie MJ. Pharmacotherapy of epilepsy: newly approved and developmental agents. CNS Drugs 2011; 25:89.
  14. Singh NA, Charlier C, Stauffer D, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 1998; 18:25.
  15. Rogawski MA. KCNQ2/KCNQ3 K+ channels and the molecular pathogenesis of epilepsy: implications for therapy. Trends Neurosci 2000; 23:393.
  16. Neubauer BA, Waldegger S, Heinzinger J, et al. KCNQ2 and KCNQ3 mutations contribute to different idiopathic epilepsy syndromes. Neurology 2008; 71:177.
  17. Simeone TA, Sanchez RM, Rho JM. Molecular biology and ontogeny of glutamate receptors in the mammalian central nervous system. J Child Neurol 2004; 19:343.
  18. Mori H, Mishina M. Structure and function of the NMDA receptor channel. Neuropharmacology 1995; 34:1219.
  19. Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 2008; 7:742.
  20. Avanzini G, Franceschetti S. Cellular biology of epileptogenesis. Lancet Neurol 2003; 2:33.
  21. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 1999; 51:7.
  22. Rogawski MA. AMPA receptors as a molecular target in epilepsy therapy. Acta Neurol Scand Suppl 2013; :9.
  23. Conn PJ. Physiological roles and therapeutic potential of metabotropic glutamate receptors. Ann N Y Acad Sci 2003; 1003:12.
  24. Ure J, Baudry M, Perassolo M. Metabotropic glutamate receptors and epilepsy. J Neurol Sci 2006; 247:1.
  25. Rakhade SN, Loeb JA. Focal reduction of neuronal glutamate transporters in human neocortical epilepsy. Epilepsia 2008; 49:226.
  26. Pleasure D. Diagnostic and pathogenic significance of glutamate receptor autoantibodies. Arch Neurol 2008; 65:589.
  27. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011; 77:179.
  28. Nabbout R. Autoimmune and inflammatory epilepsies. Epilepsia 2012; 53 Suppl 4:58.
  29. van der Hel WS, Verlinde SA, Meijer DH, et al. Hippocampal distribution of vesicular glutamate transporter 1 in patients with temporal lobe epilepsy. Epilepsia 2009; 50:1717.
  30. Sigel E, Steinmann ME. Structure, function, and modulation of GABA(A) receptors. J Biol Chem 2012; 287:40224.
  31. Ben-Ari Y. Excitatory actions of gaba during development: the nature of the nurture. Nat Rev Neurosci 2002; 3:728.
  32. Staley KJ. Wrong-way chloride transport: is it a treatable cause of some intractable seizures? Epilepsy Curr 2006; 6:124.
  33. Ben-Ari Y, Khalilov I, Kahle KT, Cherubini E. The GABA excitatory/inhibitory shift in brain maturation and neurological disorders. Neuroscientist 2012; 18:467.
  34. Rivera C, Voipio J, Payne JA, et al. The K+/Cl- co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. Nature 1999; 397:251.
  35. Simeone TA, Donevan SD, Rho JM. Molecular biology and ontogeny of gamma-aminobutyric acid (GABA) receptors in the mammalian central nervous system. J Child Neurol 2003; 18:39.
  36. Gospe SM Jr. Pyridoxine-dependent seizures: new genetic and biochemical clues to help with diagnosis and treatment. Curr Opin Neurol 2006; 19:148.
  37. D'Ambrosio R. The role of glial membrane ion channels in seizures and epileptogenesis. Pharmacol Ther 2004; 103:95.
  38. Meldrum BS, Akbar MT, Chapman AG. Glutamate receptors and transporters in genetic and acquired models of epilepsy. Epilepsy Res 1999; 36:189.
  39. de Lanerolle NC, Lee TS, Spencer DD. Astrocytes and epilepsy. Neurotherapeutics 2010; 7:424.
  40. Tian GF, Azmi H, Takano T, et al. An astrocytic basis of epilepsy. Nat Med 2005; 11:973.
  41. Aronica E, Ravizza T, Zurolo E, Vezzani A. Astrocyte immune responses in epilepsy. Glia 2012; 60:1258.
  42. Nadler JV. The recurrent mossy fiber pathway of the epileptic brain. Neurochem Res 2003; 28:1649.
  43. Buzsáki G, Draguhn A. Neuronal oscillations in cortical networks. Science 2004; 304:1926.
  44. Bouilleret V, Semah F, Chassoux F, et al. Basal ganglia involvement in temporal lobe epilepsy: a functional and morphologic study. Neurology 2008; 70:177.
  45. Staba RJ, Bragin A. High-frequency oscillations and other electrophysiological biomarkers of epilepsy: underlying mechanisms. Biomark Med 2011; 5:545.
  46. Jin MM, Chen Z. Role of gap junctions in epilepsy. Neurosci Bull 2011; 27:389.
  47. Hochman DW, Baraban SC, Owens JW, Schwartzkroin PA. Dissociation of synchronization and excitability in furosemide blockade of epileptiform activity. Science 1995; 270:99.
  48. Gnatkovsky V, Librizzi L, Trombin F, de Curtis M. Fast activity at seizure onset is mediated by inhibitory circuits in the entorhinal cortex in vitro. Ann Neurol 2008; 64:674.
  49. Emmi A, Wenzel HJ, Schwartzkroin PA, et al. Do glia have heart? Expression and functional role for ether-a-go-go currents in hippocampal astrocytes. J Neurosci 2000; 20:3915.
  50. Sutula, T, Pitkänen, A. Do Seizures Damage the Brain? Elsevier, Amsterdam 2002.
  51. Velísek L, Moshé SL. Effects of brief seizures during development. Prog Brain Res 2002; 135:355.
  52. Bertram E. The relevance of kindling for human epilepsy. Epilepsia 2007; 48 Suppl 2:65.
  53. Pitkänen A, Sutula TP. Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol 2002; 1:173.
  54. Austin JK, Caplan R. Behavioral and psychiatric comorbidities in pediatric epilepsy: toward an integrative model. Epilepsia 2007; 48:1639.
  55. Tyvaert L, Chassagnon S, Sadikot A, et al. Thalamic nuclei activity in idiopathic generalized epilepsy: an EEG-fMRI study. Neurology 2009; 73:2018.
  56. Deppe M, Kellinghaus C, Duning T, et al. Nerve fiber impairment of anterior thalamocortical circuitry in juvenile myoclonic epilepsy. Neurology 2008; 71:1981.
  57. Lin K, Carrete H Jr, Lin J, et al. Magnetic resonance spectroscopy reveals an epileptic network in juvenile myoclonic epilepsy. Epilepsia 2009; 50:1191.
  58. Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev 2003; 83:117.
  59. Heron SE, Khosravani H, Varela D, et al. Extended spectrum of idiopathic generalized epilepsies associated with CACNA1H functional variants. Ann Neurol 2007; 62:560.
  60. Chen Y, Lu J, Pan H, et al. Association between genetic variation of CACNA1H and childhood absence epilepsy. Ann Neurol 2003; 54:239.
  61. Coulter DA, Huguenard JR, Prince DA. Specific petit mal anticonvulsants reduce calcium currents in thalamic neurons. Neurosci Lett 1989; 98:74.
  62. Leresche N, Parri HR, Erdemli G, et al. On the action of the anti-absence drug ethosuximide in the rat and cat thalamus. J Neurosci 1998; 18:4842.
  63. Robinson RB, Siegelbaum SA. Hyperpolarization-activated cation currents: from molecules to physiological function. Annu Rev Physiol 2003; 65:453.
  64. Santoro B, Baram TZ. The multiple personalities of h-channels. Trends Neurosci 2003; 26:550.
  65. Poolos NP, Warner LN, Humphreys SZ, Williams S. Comparative efficacy of combination drug therapy in refractory epilepsy. Neurology 2012; 78:62.
  66. Benarroch EE. HCN channels: function and clinical implications. Neurology 2013; 80:304.
  67. Han HA, Cortez MA, Snead OC. GABA-B receptor and absence epilepsy. In: Jasper's Basic Mechanisms of the Epilepsies, Noebels JL, et al. (Eds), Oxford Univeristy Press, New York 2012. p.242.
  68. Hauser, W, Hersdorffer, D. Epilepsy: Frequency, Causes and Consequences. Demos, New York 1990.
  69. Holmes GL. Epilepsy in the developing brain: lessons from the laboratory and clinic. Epilepsia 1997; 38:12.
  70. Wong M. Advances in the pathophysiology of developmental epilepsies. Semin Pediatr Neurol 2005; 12:72.
  71. Rakhade SN, Jensen FE. Epileptogenesis in the immature brain: emerging mechanisms. Nat Rev Neurol 2009; 5:380.
  72. Brooks-Kayal AR, Shumate MD, Jin H, et al. gamma-Aminobutyric acid(A) receptor subunit expression predicts functional changes in hippocampal dentate granule cells during postnatal development. J Neurochem 2001; 77:1266.
  73. Raol YH, Lund IV, Bandyopadhyay S, et al. Enhancing GABA(A) receptor alpha 1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy. J Neurosci 2006; 26:11342.
  74. Perez Velazquez JL, Carlen PL. Gap junctions, synchrony and seizures. Trends Neurosci 2000; 23:68.
  75. Margineanu DG. Epileptic hypersynchrony revisited. Neuroreport 2010; 21:963.
  76. Swann JW, Hablitz JJ. Cellular abnormalities and synaptic plasticity in seizure disorders of the immature nervous system. Ment Retard Dev Disabil Res Rev 2000; 6:258.
  77. Haglund MM, Schwartzkroin PA. Role of Na-K pump potassium regulation and IPSPs in seizures and spreading depression in immature rabbit hippocampal slices. J Neurophysiol 1990; 63:225.